SE0103838D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103838D0
SE0103838D0 SE0103838A SE0103838A SE0103838D0 SE 0103838 D0 SE0103838 D0 SE 0103838D0 SE 0103838 A SE0103838 A SE 0103838A SE 0103838 A SE0103838 A SE 0103838A SE 0103838 D0 SE0103838 D0 SE 0103838D0
Authority
SE
Sweden
Prior art keywords
alpha
drug
formulation
methylpropiono
fluorophenylsulphonyl
Prior art date
Application number
SE0103838A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103838A priority Critical patent/SE0103838D0/sv
Publication of SE0103838D0 publication Critical patent/SE0103838D0/sv
Priority to PCT/GB2002/005158 priority patent/WO2003043630A1/en
Priority to AU2002339169A priority patent/AU2002339169A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SE0103838A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103838D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
PCT/GB2002/005158 WO2003043630A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
AU2002339169A AU2002339169A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103838D0 true SE0103838D0 (sv) 2001-11-16

Family

ID=20286022

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (3)

Country Link
AU (1) AU2002339169A1 (sv)
SE (1) SE0103838D0 (sv)
WO (1) WO2003043630A1 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007014393A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN104146974B (zh) * 2014-08-14 2016-09-07 杭州华东医药集团新药研究院有限公司 一种含来曲唑的组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
CA2439366A1 (en) * 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
EE200300476A (et) * 2001-04-02 2003-12-15 Astrazeneca Ab 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon

Also Published As

Publication number Publication date
WO2003043630A1 (en) 2003-05-30
AU2002339169A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
AR032912A1 (es) Formulacion farmaceutica
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
SE0103839D0 (sv) Pharmaceutical formulation & product
CY1115056T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγηση
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
HK1068606A1 (en) Novel aminobenzoephenones
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0103424D0 (sv) Pharmaceutical formulation
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
SE0102887D0 (sv) New formulation
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
JOP20220038A1 (ar) عوامل مضادة للملاريا
BRPI0416316A (pt) combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
HK1061530A1 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy.